VIDEO: CAR T-cell therapy ‘showed efficacy’ in prostate cancer subgroup
Click Here to Manage Email Alerts
Healio spoke with Tanya Dorff, MD, section chief of the genitourinary disease program at City of Hope, about a study evaluating the use of a chimeric antigen receptor T-cell therapy in a subgroup of patients with prostate cancer.
The study, which was presented by Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, at the 2022 ASCO Genitourinary Cancers Symposium, evaluated the use of an autologous CAR-T cell therapy that targeted prostate-specific membrane antigen (PSMA) in patients with metastatic castration-resistant prostate cancer.
According to Dorff, the phase 1 results “clearly showed efficacy” and included a dataset from a patient who had radiographic response to treatment, PSMA positron emission tomography response, PSA response, and biopsies that demonstrated tumor eradication and infiltration of T cells.
Dorff noted that the presentation included “really robust data showing that this PSMA-targeted CAR-T can induce a really big remission, and we’re hoping it will stay durable.”
She added that “there’s already a few months of durability in the abstract, but [it’s] just exciting to see that not one CAR-T construct, but two separate CAR-T constructs have potential in prostate cancer,” referencing data she presented at the meeting on the use of a PSCA-targeted CAR T-cell therapy in patients with castration-resistant prostate cancer.
Collapse
Read more about
Click Here to Manage Email Alerts